Cargando…

Mortality in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study

INTRODUCTION: Pimavanserin is approved in the USA to treat hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). OBJECTIVES: We evaluated mortality in patients with PDP after initiation of pimavanserin or comparator atypical antipsychotics, overall, over time, and across...

Descripción completa

Detalles Bibliográficos
Autores principales:	Layton, J. Bradley, Forns, Joan, McQuay, Lisa J., Danysh, Heather E., Dempsey, Colleen, Anthony, Mary S., Turner, Mary Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883317/ https://www.ncbi.nlm.nih.gov/pubmed/36517664 http://dx.doi.org/10.1007/s40264-022-01260-6

Ejemplares similares

Falls and Fractures in Patients with Parkinson’s Disease-Related Psychosis Treated with Pimavanserin vs Atypical Antipsychotics: A Cohort Study
por: Layton, J. Bradley, et al.
Publicado: (2021)

Clinical outcomes and treatment patterns of older adults with dementia-related psychosis by dementia type in the United States
por: Forns, Joan, et al.
Publicado: (2022)

Increased risk of falls and fractures in patients with psychosis and Parkinson disease
por: Forns, Joan, et al.
Publicado: (2021)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs, Brianna L, et al.
Publicado: (2017)

Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
por: Dashtipour, Khashayar, et al.
Publicado: (2021)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2022)

Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review
por: Patel, Rikinkumar S, et al.
Publicado: (2019)

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin
por: Caraci, Filippo, et al.
Publicado: (2020)

On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
por: Hacksell, Uli, et al.
Publicado: (2014)

Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: A review of the literature
por: Touma, Katie T. B., et al.
Publicado: (2018)

Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis
por: Abler, Victor, et al.
Publicado: (2022)

Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis
por: Brown, Joshua D, et al.
Publicado: (2021)

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
por: Sellers, Jessie, et al.
Publicado: (2019)

Pimavanserin: A Novel Antipsychotic With Potentials to Address an Unmet Need of Older Adults With Dementia-Related Psychosis
por: Yunusa, Ismaeel, et al.
Publicado: (2020)

Pimavanserin: Potential Treatment For Dementia-Related Psychosis
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Dementia-related psychosis and the potential role for pimavanserin
por: Cummings, Jeffery L., et al.
Publicado: (2022)

Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions
por: Heim, Beatrice, et al.
Publicado: (2023)

Long-term outcomes with pimavanserin for psychosis in clinical practice
por: Akbar, Umer, et al.
Publicado: (2022)

Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
por: Espay, Alberto J., et al.
Publicado: (2018)

Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis
por: Isaacson, Stuart H., et al.
Publicado: (2020)

Atypical antipsychotic therapy in Parkinson's disease psychosis: A retrospective study
por: Yuan, Mei, et al.
Publicado: (2017)

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
por: Srinivasan, Shilpa, et al.
Publicado: (2020)

HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2020)

Erratum to: HARMONY Study: Pimavanserin Significantly Prolongs Time to Relapse of Dementia-Related Psychosis
por: Tariot, Pierre, et al.
Publicado: (2021)

Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis
por: Zhang, Han, et al.
Publicado: (2019)

Pimavanserin Treatment for Psychosis in Patients with Dementia with Lewy Bodies: A Case Series
por: Rothenberg, Kasia Gustaw, et al.
Publicado: (2023)

Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
por: Ramachandran, Sharavan, et al.
Publicado: (2020)

Onset of action of atypical and typical antipsychotics in the treatment of acute psychosis
por: Mousavi, Seyed Ghafur, et al.
Publicado: (2013)

Psychosis in Parkinson’s disease and parkinsonism in antipsychotic-naive schizophrenia spectrum psychosis: clinical, nosological and pathobiological challenges
por: Waddington, John L.
Publicado: (2020)

T42. HIGH ADHERENCE TO CURRENT ANTIPSYCHOTIC AND ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL TO EVALUATE THE TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Abbs, Brandon, et al.
Publicado: (2020)

The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease
por: Divac, Nevena, et al.
Publicado: (2016)

Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis
por: Jethwa, Ketan Dipak, et al.
Publicado: (2015)

An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression
por: DeKarske, Daryl, et al.
Publicado: (2020)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Atypical antipsychotics, more than just an antipsychotic
por: Tendilla-Beltrán, Hiram, et al.
Publicado: (2020)

Impact of specialty pharmacist integration on time to medication access for pimavanserin
por: Livezey, Sabrina, et al.
Publicado: (2019)

Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment
por: Ramachandran, Sharavan, et al.
Publicado: (2021)

T41. SAFETY PROFILE OF ADJUNCTIVE PIMAVANSERIN IN THE ENHANCE STUDY, A PHASE 3 TRIAL FOR THE POTENTIAL TREATMENT OF SCHIZOPHRENIA IN PATIENTS WITH AN INADEQUATE RESPONSE TO ANTIPSYCHOTIC TREATMENT
por: Bugarski-Kirola, Dragana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tlgvo76s0luolbi3sqmbe6v9cn